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doi:10.1016/j.cancergrved in breast tumors as a manifestation of genomic
instability. To date, numerous oncogenes or tumor suppressors on some of these regions have been
characterized. An increasing body of evidence suggests that such regions also harbor microRNA
genes with crucial regulatory roles in cellular processes and disease mechanisms, including cancer.
Here, we investigated 35 microRNAs localized to common genomic gain and/or loss regions in
breast cancers. To examine amplification or loss of these microRNAs as a result of genomic insta-
bility, we performed semiquantitative duplex polymerase chain reaction in 20 breast cancer cell
lines, 2 immortalized mammary cell lines, and 2 normal DNA controls. A comprehensive DNA fold
number change data for 35 microRNA genes on chromosomal gain/loss regions are presented in
breast cancer cells. A 23% (8/35) of the investigated microRNAs showed significant fold number
increases (greater than fourfold) compared to GAPDH in one or more of the breast cell lines.
Although no homozygous deletions were detected, fold number decreases indicating potential loss
regions were observed for 26% (9/35) of the investigated microRNAs. Such fold number changes
may point out some of these microRNAs as potential targets of the genomic instability regions as
oncogene and tumor suppressor candidates.  2009 Elsevier Inc. All rights reserved.1. Introduction
Genomic instability is commonly seen in breast cancers.
So far, various potent oncogenes and tumor suppressors
located on some of these common instability regions have
been identified. In addition to the coding genes, microRNA
genes are also found to be located on genomic instability
regions and chromosomal fragile sites [1,2]. Moreover,
numerous murine microRNA loci have been indicated as
common retroviral integration sites [3].
MicroRNAs are about 18e24 nucleotide transcripts that
can bind to the 3’ untranslated regions (UTR) of target
mRNAs and either prevent their translation or cause degra-
dation [4e7]. Recent research suggests important regula-
tory roles of such noncoding RNA in various processes,
such as those directing pluripotency, differentiation,
morphogenesis, cell cycle regulation, metabolism, and
immune system pathways [8,9].
A growing body of evidence suggests deregulated
expression of microRNAs in various tumors. Abnormalauthor. Tel.: þ90 (312) 210-5043; fax: þ 90 (312)
rson@metu.edu.tr (A.E. Erson).
front matter  2009 Elsevier Inc. All rights reserved.
encyto.2008.09.009microRNA expression is, therefore, linked to altered levels
of proteins that may have significant roles during the initia-
tion or maintenance of the neoplastic phenotype in different
cancer types. In fact, deregulated microRNA expression pro-
files have been shown to effectively differentiate normal
breast tissue from breast tumors [10]. As evidence continues
to build up linking microRNAs to cancer, hsa-mir-21, map-
ped on an amplicon region (17q23), was found to be overex-
pressed in breast cancers, glioblastomas, pancreatic cancers,
hepatacellular cancers, cholangiocarcinomas, ovarian, and
colorectal cancers [10e18]. So far, identified targets of
hsa-mir-21, PTEN, PDCD4, and TPM1 are known to be
involved in cell survival and transformation processes
[14,17,19]. Therefore, identification of deregulated micro-
RNAs and their target mRNAs provides new avenues toward
understanding the tumorigenesis processes.
Based on the fact that breast cancers demonstrate high
genomic instability phenotypes, we investigated the status
of microRNA genes on such gain/loss regions in breast can-
cer cell lines to pioneer further expression and functional
analysis for microRNA genes that may be targets of ampli-
fication or regions of loss. While the majority of microRNA
genes had various degrees of fold number increases or
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genes showed significant fold number increases (more than
fourfold) compared to GAPDH in one or more of the breast
cell lines. No homozygous deletions were detected, but fold
number decreases indicating potential loss regions were
observed for 26% (9/35) of the investigated microRNAs.2. Materials and methods
2.1. Cancer cell line DNA
Twenty breast cancer cell lines [BT20, BT474, BT549,
CAL51, DU4475, Hs578T, MCF7, MDA-MB157, MDA-
MB231, MDA-MB361, MDA-MB435 (breast origin ques-
tioned by [20]), MDA-MB468, SUM52, SUM102,
SUM149, SUM159, SUM185, SUM229, SK-BR3, and
T47D] and 2 immortalized, nontumorigenic mammary cell
lines (HPV4-12 and MCF10) DNA samples were kindly
provided by E.M. Petty (University of Michigan, Ann
Arbor, MI).
2.2. Selection of common genomic gain/loss regions
Publications on homozygous deletion (HD), loss of
heterozygosity (LOH), and amplification regions in breast
cancer cells were screened to build a list of frequent and com-
mon genomic gain/loss regions in breast cancer. Two
approaches were used to find microRNAs mapping to theseTable 1
List of microRNA genes on genomic instability regions
Loci Gain / loss Samples
1 2q31~q32 Gain MDA-MB-231
2q Loss BT
2 3p21 Loss BCCL and BT
3p Loss BT
3 3q Gain BT
4 3q13.3 Loss MCF7
5 5q33 Loss BT
6 8p11~p12 Gain BCCL and BT
8p11~p21 Loss BT
7 8p21 Loss BT
8 8p21~p23 Loss BCCL and BT
Gain BT
9 11q23~q24 Gain BT
Loss BT
10 13q14 Loss BCCL and BT
11 13q31 Gain BCCL
12 17q22~q24 Gain BCCL and BT
13 17q23 Gain BCCL and BT
14 20p Gain BCCL and BT
15 21q21 Loss BT
16 Xq21 Loss BCCL
Abbreviations: BCCL, breast cancer cell lines; BT, breast tumors.regions. First, boundaries for these regions were extracted
from the UCSC Genome Browser (Genome Bioinformatics
Group of UC Santa Cruz, Human Genome assembly, May
2004) using single-nucleotide polymorphism (SNP) marker
information, when available. microRNA genes located
within these boundaries and/or chromosomal bands were
then identified from the miRBase database (version 7.1; Wel-
come Trust Sanger Institute). Second, all known microRNA
sequences were combined back to back in FASTA format and
were blasted against the selected genomic gain/loss regions
to localize any microRNA genes (Tables 1 and 2).2.3. Semi-quantitative duplex PCR and densitometry
analysis
Primer sets for microRNA genes on selected chromo-
somal regions were designed by using the Primer3 program
(version 0.2; Whitehead Institute for Biomedical Research,
Cambridge, MA; Table 3). MicroRNA genes were co-am-
plified with an internal control gene, GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase), by semiquantitative
duplex PCR, which was optimized and performed as de-
scribed previously [21]. Optimization of PCR in control
DNA samples involved two major steps: (1) coamplifica-
tion of microRNA gene primers with alternating GAPDH
primer concentrations to obtain similar-intensity bands
and (2) optimization of PCR cycle number for each reaction































Chromosomal coordinates of microRNAs according to UCSC Genome
Browser
microRNAs Chromosomal coordinates
1 hsa-mir-10b 2: 176,723,277-176,723,386 [þ]
2 hsa-mir-138-1 3: 44,130,708-44,130,806 [þ]
3 hsa-mir-425 3: 49,032,585-49,032,671 [e]
4 hsa-mir-191 3: 49,033,055-49,033,146 [e]
5 hsa-let-7g 3: 52,277,334-52,277,417 [e]
6 hsa-mir-135a-1 3: 52,303,275-52,303,364 [e]
7 hsa-mir-198 3: 121,597,205-121,597,266 [e]
8 hsa-mir-15b 3: 161,605,070-161,605,167 [þ]
9 hsa-mir-16-2 3: 161,605,227-161,605,307 [þ]
10 hsa-mir-145 5: 148,790,402-148,790,489 [þ]
11 hsa-mir-143 5: 148,788,674-148,788,779 [þ]
12 hsa-mir-383 8: 14,755,318-14,755,390 [e]
13 hsa-mir-486 8: 41,637,116-41,637,183 [e]
14 hsa-mir-320a 8: 22,158,420-22,158,501 [e]
15 hsa-mir-34c 11: 110,889,374-110,889,450 [þ]
16 hsa-mir-125b-1 11: 121,475,675-121,475,762 [e]
17 hsa-let-7a-2 11: 121,522,440-121,522,511 [e]
18 hsa-mir-100 11: 121,528,147-121,528,226 [e]
19 hsa-mir-16-1 13: 49,521,110-49,521,198 [e]
20 hsa-mir-15a 13: 49,521,256-49,521,338 [e]
21 hsa-mir-17 13: 90,800,860-90,800,943 [þ]
22 hsa-mir-18a 13: 90,801,006-90,801,076 [þ]
23 hsa-mir-19a 13: 90,801,146-90,801,227 [þ]
24 hsa-mir-20a 13: 90,801,320-90,801,390 [þ]
25 hsa-mir-19b-1 13: 90,801,447-90,801,533 [þ]
26 hsa-mir-92a-1 13: 90,801,569-90,801,646 [þ]
27 hsa-mir-142 17: 53,763,592-53,763,678 [e]
28 hsa-mir-301a 17: 54,583,279-54,583,364 [e]
29 hsa-mir-21 17: 55,273,409-55,273,480 [þ]
30 hsa-mir-633 17: 58,375,308-58,375,405 [þ]
31 hsa-mir-103-2 20: 3,846,141-3,846,218 [þ]
32 hsa-mir-125b-2 21: 16,884,428-16,884,516 [þ]
33 hsa-mir-384 X: 76,056,092-76,056,179 [e]
34 hsa-mir-325 X: 76,142,220-761,42,317 [e]
35 hsa-mir-361 X: 85,045,297-85,045,368 [e]
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ium bromideestained 2% agarose gels, visualized, and
documented under ultraviolet light. Band intensities for
the microRNA and GAPDH PCR products were quantified
by using the densitometric image processing and analysis
program Scion Image (version beta 3b; National Institutes
of Health, Bethesda, MD) and by visual inspection. Ratio
of band intensities for the microRNA and GAPDH were
calculated. Cancer cell line ratios were normalized using
the mean of the signals from normal DNA samples (N1,
N2). Fold changes of 35 microRNA genes compared to
GAPDH in 20 breast cancer cell lines (BCCL) and two im-
mortalized cell lines were calculated as follows;Fold change5
BCCLðmicroRNA=GAPDHÞ
AVGðN1;N2ÞðmicroRNA=GAPDHÞFold changes for each microRNA in cancer cells versus
controls were then classified with the following cut-off
values; less than 0.3-fold (loss), 0.3e2.0-fold (no signifi-
cant change), 2.0e4.0-fold (gain), and > 4-folds (and/or
saturated bands due to significant amplification) (significantgain). For reverse-transcription polymerase chain reaction
(RT-PCR), DNase-treated RNA (1 mg) was used to synthe-
size cDNA using both oligodT primers and random
hexamers.3. Results and Discussion
Common breast cancererelated genomic gain/loss
regions were selected from the literature. Screening for
microRNA genes located within the boundaries of these
chromosomal regions resulted in the identification of more
than 30 known microRNA genes (Table 1).
Primers were designed to investigate genomic loss or
gain of microRNA genes located on breast cancererelated
genomic regions. Thirty-five microRNA genes were
successfully co-amplified with GAPDH primers in 20
breast cancer cell lines, 2 immortalized mammary cell
lines, and 2 normal DNA controls. Ratios of the microRNA
and GAPDH PCR product bands were then detected by
densitometry for cancer cell lines and compared to the av-
erage values of the two normal control DNA samples. To
minimize insensitivity of semi-quantitative PCR results
and to be stringent about calling a region lost, only micro-
RNA/GAPDH ratios less than 0.3-fold compared to normal
samples were considered as losses and increases of more
than 2-fold were indicated as gains (Fig. 1). No HD were
observed for any of the microRNA genes in the examined
cell lines. Taking limits of duplex PCR into account, we
focused on consistent patterns of amplification or loss of
microRNA genes across several cell lines, whereas no
significant fold number changes were detected for some
microRNAs, such as hsa-mir-486 and hsa-mir-10b. Hsa-
mir-10b, on 2q31.1, was recently reported to be highly ex-
pressed in metastatic breast cancer cells (e.g., MDA-MB-
231) contributing to invasion and metastasis [22]. We did
not detect any significant amplification in any of the cell
lines for this microRNA gene, therefore DNA amplification
may not be a common reason of overexpression of this
microRNA in breast cancer cells.
Among the selected breast cancererelated genomic
regions, some were defined by broad chromosomal bound-
aries, so it was not unusual to find different studies report-
ing the same region to harbor either genomic loss or gain.
In breast cancer cells, we also observed that some micro-
RNA located on regions of loss showed fold number
increases, whereas some others located on gain regions
showed fold number decreases. For example, hsa-mir-384
resides on Xp21.2, which was indicated as a region of loss
[23]. While we detected loss for Hs578T, MDA-MB-231
demonstrated a threefold increase in the microRNA PCR
product compared to GAPDH and normal DNA samples
(Fig. 2A). While some of these similar results may be partly
explained by the insensitivity of semi-quantitative PCR, it
may also suggest how complicated genomic instability
may manifest in breast cancers.
Table 3
Primer sequences for microRNA genes and GAPDH
microRNA Primer sequences (5’ / 3’)
hsa-mir-10b F: TAATAAAGCCGCCATCCTTG, R: CTGGCTATTCCGAAGAAACG
hsa-mir-let7g F: GGTTTCCCAGAGATGAGCAG, R: AGCCTCTGCTGTGAGGATGT
hsa-mir-135a-1 F: CTGTCCTGCCTCCTTTTGAG, R: GAAGAAGTGCCTGCAAGAGC
hsa-mir-138-1 F: AGCAGCACAAAGGCATCTCT, R: CTCTGTGACGGGTGTAGCTG
hsa-mir-425 F: CCACCCCCATTCCTTTTAAT, R: CAGGTCATGCACCTTCAGAAT
hsa-mir-191 F:AAGTATGTCTGGGGGTCAGG, R: ACAACCTACTCCCGGGTCTT
hsa-mir-198 F:GCCGGAGGTTAAACATGAAA, R: CCCAGCCTACCAATATGCTC
hsa-mir-15b F: AGAACGGCCTGCAGAGATAA, R: CGTGCTGCTAGAGTGGAACA
hsa-mir-16-2 F: TGTTCGTTTTATGTTTGGATGA, R: AGTGGTTCCACCAAGTAAGTCA
hsa-mir-145 F: GGCTGGATGCAGAAGAGAAC, R: CAGGGACAGCCTTCTTCTTG
hsa-mir-143 F: CCCTCTAACACCCCTTCTCC, R: AACTTCCCCAGCATCACAAG
hsa-mir-486 F: CCTGGGGTGTGAATGGTAAC, R: ATCTCCAGCAGGTGTGTGTG
hsa-mir-320 F: GAGGCGAATCCTCACATTG, R: GGGACTGGGCCACAGTATTT
hsa-mir-383 F: AGTCCACCAAATGCAGTTCC, R: ACTTCAGAATCTCCCCGTCA
hsa-mir-34c F: TTGAGCTCCAACTCAACCAA, R: GATGCACAGGCAGCTCATT
hsa-mir-125b-1 F: ACCAAATTTCCAGGATGCAA, R: CGAACAGAAATTGCCTGTCA
hsa-mir-let-7a-2 F: ATAGGGAGAAAAGGCCTGGA, R: ATGGCCCAAATAGGTGACAG
hsa-mir-100 F: AGGTCTCCTTCCTCCACCTC, R: GTCACAGCCCCAAAAGAGAG
hsa-mir-16-1 F: TGAAAAAGACTATCAATAAAACTGAAAA, R: CCATATTGTGCTGCCTCAAA
hsa-mir-15a F: TACGTGCTGCTAAGGCACTG, R: ATTCTTTAGGCGCGAATGTG
hsa-mir-19a F: TGCCCTAAGTGCTCCTTCTG, R: CCAGGCAGATTCTACATCGAC
hsa-mir-20a F: CGATGTAGAATCTGCCTGGTC, R: GGATGCAAACCTGCAAAACT
hsa-mir 19b-1 F: GCCCAATCAAACTGTCCTGT, R: ACCGATCCCAACCTGTGTAG
hsa-mir-17 F: CCCCATTAGGGATTATGCTG, R: CCTGCACTTTAAAGCCCAACT
hsa-mir 18a F: GGCACTTGTAGCATTATGGTGA, R TGCAAAACTAACAGAGGACTGC:
hsa-mir-92-1 F: CCATGCAAAACTGACTGTGG, R: CAGTGGAAGTCGAAATCTTCAG
hsa-mir-142 F: CAGGGTTCCACATGTCCAG, R: CTGAGTCACCGCCCACAAG
hsa-mir-301 F: CTCATTTAGACAAACCATAACAACTT, R: CATCAATAAGCAACATCACTTTGA
hsa-mir-21 F: CCATTGGGATGTTTTTGATTG, R: TCCATAAAATCCTCCCTCCA
hsa-mir-633 F: AGGACTGGGTTTGAGTCCTG, R: TTAGACATTCCTCCTGGTGAA
hsa-mir-103-2 F:CCCTAGGGAGGAATCCAGAG, R: AGCCATAAGCTGCACCAACT
hsa-mir-125b-2 F: TCGTCGTGATTACTCAGCTCAT, R: CAGGGATCAGCTGGAAGAAG
hsa-mir-384 F: TGGCCAGTTAGCATCTTGAA, R: TCAGGCCTGCAGAAATAGTG
hsa-mir-325 F: TCCTTTTCACCCCTCAACAC, R: GGATTCAAGTCCACAGAACCA
hsa-mir-361 F:GGAGCTCAACCATACCAGGA R: TTGGGCATATGTGACCATCA
GAPDH F: TGCCTTCTTGCCTCTTGTCT, R: CTGCAAATGAGCCTACAGCA
18 S.D. Selcuklu et al. / Cancer Genetics and Cytogenetics 189 (2009) 15e23Similarly, hsa-mir-191 on chromosomal band 3p21
mostly showed fold number increases in SUM185, CAL51,
and DU4475 cells. Although 3p21 is usually indicated as
a loss region in breast and lung cancers [1], amplification
of this microRNA gene was consistent with recent reports
suggesting hsa-mir-191 overexpression in breast cancer cell
lines [24] and colon cancers [25]. Moreover, according to
a recently generated comprehensive copy number variation
(CNV) map of the human genome [26], chromosomal bands
3p21 and 8p21 were denoted as CNV loci. Chromosomal
bands 3p21 and 8p21 harbor hsa-mir-138-1 (Fig. 2B), hsa-
let-7g (overexpressed in colon cancers [27]), and hsa-
mir-320a, respectively. Therefore, for the microRNA on
these chromosomal bands, fold number increases and/or de-
creases in different cells may also be an indication of CNV.
Targets of these microRNA will be interesting to evaluate
the role of CNV that may be seen on these chromosomal
bands. Other chromosome 3q microRNAs [hsa-mir-198
and hsa-mir-15b, 40 megabases (Mb) apart from each other]
demonstrated low to significant fold number increases in
more than two cell lines. Hsa-mir-15b demonstrated thefollowing fold number increases: 2.6 for MCF7, 2.5 for
T47D, and 2 for both BT474 and MDA-MB-468. Therefore,
gains were indicated for these cell lines in Fig. 1 because they
were above the threshold of twofold. Hsa-mir-16-2 [60 base
pairs (bp) away from hsa-mir-15b] also demonstrated a simi-
lar amplification pattern (1.2 for MCF7, 1.7 for T47D, 1.4 for
BT474, and 1.6 for MDA-MB-468), but since all were below
the threshold value of twofold, no gain was indicated for
these cell lines in Fig. 1.
Surprisingly, hsa-mir-145 on 5q, a region to harbor mul-
tiple loss of heterozygosity regions [28], was amplified in
13 cell lines, including MCF10 and HPV4-12, whereas
no significant fold number decrease was observed. Hsa-
mir-145 is known to be down-regulated in different
tumors such as breast [10,24] and ovarian [15]. However,
when compared to the SNP arrayebased LOH and copy
number analysis data from Cancer Genome Project (CGP)
of the Wellcome Trust Sanger Institute (http://www.sanger.
ac.uk/genetics/CGP), some breast cancer cell lines (e.g.,
MCF7, MDA-MB-157, and BT549) were indeed reported















































































































































































































































































































































































































































































Fig. 1. Fold number changes for the 35 microRNA genes mapping to selected genomic gain/loss regions in breast cancers. Densitometric analysis results of
microRNA and GAPDH PCR products of cancer cell lines were compared to that of normal DNA.Fold changes for each microRNA in cancer cells versus
controls were classified with the following cut-off values; less than 0.3-fold (loss, ), 0.3- to 2.0-fold (no significant change, ), 2.0e4.0 fold (gain, ),
and 4-fold or higher (and/or saturated bands due to significant amplification; significant gain, ).
19S.D. Selcuklu et al. / Cancer Genetics and Cytogenetics 189 (2009) 15e23140- to 50-Mb region of chromosome 5q32. Both data
suggest transcriptional regulation to be a more plausible
mechanism than genomic loss for the down-regulation of
hsa-mir-145 in breast cancer cells.
Hsa-mir-34b and hsa-mir-34c on 11q23 are recently
shown to be normally up-regulated in response to DNA
damage and oncogenic stress in a p53-dependent manner
and to decrease p53-mediated cell death when hsa-mir-34
function was reduced [29]. We detected low to moderate
fold number increase of hsa-mir-34c in two breast cell
lines, whereas we failed to generate a PCR product for
hsa-mir-34b. According to these results, transcriptional reg-
ulation seems to be a more plausible explanation than geno-
mic loss for these microRNA. Expression status of these
microRNA genes will be crucial in revealing their roles
in breast tumorigenesis.
Consistent with the finding that hsa-mir-125b-1 on 11q24
is downregulated in ovarian cancers [15], we observed a fold
number decrease in four cell lines. Surprisingly, two others,
especially T47D, showed a fold number increase compared
to controls. Hsa-let-7a-2 and hsa-mir-100, separated from
each other by 5 kilobases, also demonstrated a conserved sig-
nificant amplification pattern in MDA-MB-231 and T47D
cells. Interestingly, in Drosophila, mir-100, mir-125, and
let-7 are all clustered within an 800-bp region on chromo-
some 2L and up-regulation of these miRNA and the down-
regulation of mir-34 requires the hormone ecdysone during
development [30]. Thus, expression and functional analysis
of 11q24 microRNA and possibly mir-34 family membersin breast cancers may potentially help to establish such a co-
operative role in mammalian cells.
Hsa-mir-16-1 and hsa-mir-15a have been indicated as tu-
mor suppressor genes in leukemia [31]. We did not observe
any fold number decreases, to indicate LOH or HD in any
of the breast cancer cell lines. The roles of these microRNAs
in breast tumorigenesis are yet to be established, but if their
deregulated expression contributes to breast tumorigenesis
as it does in leukemia, genomic loss does not seem to be com-
mon, at least among cell lines. Interestingly, low to moderate
fold number increases were observed for some cells (e.g.,
CAL51) for both hsa-mir-16-1 and hsa-mir-15a. While this
result may be due to the semi-quantitative nature of our ap-
proach, it is also possible that expression data may also not
correlate with genomic level gains or losses.
Chromosomal band 13q31.1, harboring the microRNA-
17-92 cluster, was also analyzed in breast cancer cell lines.
This cluster is known to be overexpressed in lung cancers
and lymphomas [32e34]. We did not detect a significant
genomic amplification pattern for the 17-92 cluster in
breast cancer cell lines. Especially for hsa-mir-19a and
hsa-mir-19b-1, the microRNA PCR product bands were
not even as significantly amplified as the GAPDH bands
in SUM229 and MDA-MB-435 cell lines (Fig. 3), suggest-
ing that amplification of these microRNA genes may not be
a common event in breast cancer cell lines, if this cluster
also harbors potent oncogenes with roles during breast
tumorigenesis. Interestingly, when compared to the CGP
of the Wellcome Trust Sanger Institute, we noticed
Fig. 2. Genomic gain or loss of microRNA genes detected by semi-quantitative duplex PCR. (A) Hsa-mir-384 (chromosome Xq21.2) and GAPDH primers
were co-amplified in 20 breast cancer cell lines, 2 immortalized mammary cell lines (denoted by asterisk), and 2 normal DNA controls (N1 and N2). MDA-
MB-231 showed more than 2-fold increase (Fig. 1, ), whereas Hs578T demonstrated a 0.3-fold decrease (Fig. 1, ) in comparison to GAPDH and normal
control DNA samples. (B) Hsa-mir-138-1 (chromosome 3p21) and GAPDH primers were co-amplified in 20 breast cancer cell lines, 2 immortalized mam-
mary cell lines (denoted by asterisk), and 2 normal DNA controls (N1 and N2). Hsa-mir-138-1 was found to be amplified more than twofold in CAL51 and
T47D cells (Fig. 1, ) and more than fourfold (Fig. 1, ) in MDA-MB231 cells, compared to GAPDH and to normal control DNA samples.
20 S.D. Selcuklu et al. / Cancer Genetics and Cytogenetics 189 (2009) 15e23potential LOH and HD of the 90-Mb region of chromosome
13 in some of the cell lines such as MDA-MB-231, MDA-
MB-157, and Hs578T. In agreement with this, Eiriksdottir
et al. [35] reported 13q31~qq34 as one of the three LOH
regions on 13q in breast cancer. Moreover, Hossain et al.
[36] reported hsa-mir-17, a member of the 17-92 cluster,
as a tumor suppressor in breast cancer cells because expres-
sion of hsa-mir-17 was low in breast cancer cell lines and
down-regulation of AIB1 (Amplified in Breast Cancer 1)
by hsa-mir-17 resulted in decreased proliferation of breast
cancer cells. In the same study, hsa-mir-17 was also shown
to abrogate the insulin-like growth factor 1emediated,
anchorage-independent growth of breast cancer cells.
Zhang et al. [37] further indicated that 13q31~q34microRNAs were among the 24 that showed copy number
losses in ovarian, breast, and melanoma cells.
A significant amplification pattern was observed for
microRNA genes on the 17q22~q23 region. Hsa-mir-301a
on 17q22 showed amplification in 18% (4/22) of cell lines.
Hsa-mir-21 and hsa-mir-633, located on 17q23, showed
consistent and significant amplification in MCF7, MDA-
MB-231 (more than fourfold), and T47D. These findings
were in concordance with the previous data on 17q23, a fre-
quently amplified chromosomal area that harbors amplified
oncogene candidates in breast cancers [21,38]. In addition
to coding genes in this known amplicon, amplified micro-
RNA genes are also interesting oncogene candidates,
including hsa-mir-21.
Fig. 3. Semi-quantitative PCR for the microRNA-17-92 cluster. No sig-
nificant amplification was detected for this microRNA cluster.
Fig. 4. Duplex RT-PCR for hsa-mir-383 and GAPDH. 1. MCF7, 2. MDA-
MB-231, 3. HeLa, 4. Normal Breast cDNA, 5. No cDNA, 6. MCF7, 7.
MDA-MB-231, 8. HeLa, 9. Normal Breast cDNA. cDNA samples in
1e4 were prepared using oligodT primers and those in samples 6e9 by
random hexamers. No significant difference was detected among samples
by densitometry.
21S.D. Selcuklu et al. / Cancer Genetics and Cytogenetics 189 (2009) 15e23Hsa-mir-125b-2 maps to the 16-Mb region of chromo-
some 21. A 6-centimorgan deletion interval of 21q21
between loci D21S1432 (16 Mb) and D21S1437 (20 Mb)
was reported previously [39], with the possibility that one
or more tumor suppressor genes associated with breast
cancer may exist between these markers. Therefore, consis-
tently decreased fold numbers for this microRNA in two
cell lines could be significant and may point out this micro-
RNA gene as a potential tumor suppressor gene. Deletion
regions at chromosomal band 21q21 are also reported for
other malignancies, such as lung cancers [40] and neuro-
blastomas [41]. Consistent with our results, hsa-mir-125b-2
was specifically mapped to a HD region of chromosomal
band 21q11~q21 in lung cancers [42].
On Xq21, we detected mostly low gain for hsa-mir-384,
hsa-mir-325, and hsa-mir-361. The CGP of the Wellcome
Trust Sanger Institute data suggest the presence of heteroge-
neous amplification and regions of loss on this chromosome
for the investigated cell lines. Roles and targets of these
microRNAs in neoplastic growth are yet to be investigated.
We also chose a representative microRNA (hsa-mir-383)
that resides on a chromosomal area (8p21~8p24), which
was reported to be mostly lost in tumors but also amplified
in some others (Table 1), and performed RT-PCR. As the
DNA fold number data did not suggest any loss for this
microRNA (suggested low gains), the RT-PCR results were
in agreement with the DNA data, showing similar levels of
the precursor structure compared to a normal breast cDNA
sample (RNA from Ambion, Austin, TX; Fig. 4).
Throughout the study, two immortalized mammary cell
lines (MCF10 and HPV4-12) also demonstrated fold differ-
ences compared to the control DNA samples for some micro-
RNA genes. For MCF10, we detected fold number increases
(2.3-fold for hsa-mir-145 and 2.7-fold for hsa-mir-361) and
fold number decreases (! 0.3-fold) of hsa-mir-19a and
hsa-mir-125b-2. For the other immortalized cell line,
HPV4-12, we detected fold number decreases for hsa-
mir-320a and hsa-mir-19b-1. Such genomic changes maybe expected to result from immortalization and continuous
passaging in the laboratories [43].
The internal control of choice in this study, GAPDH,
resides on the chromosome 12p13 band, which was indi-
cated as a rare amplicon region in breast cancer cells
[44]. GAPDH, however, resides 3 Mb away from the ampli-
con boundaries mentioned. Consistent with this, we did not
observe a continuous GAPDH PCR product amplification
pattern in any specific cell line.
In summary, our results suggest that a significant num-
ber of microRNA genes on genomic gain/loss regions in
breast cancers indeed have DNA level amplification or los-
ses. It should be emphasized that the aneuploidy status of
these cell lines may affect the results, and that fold number
changes may not always reflect the copy number changes of
these microRNA genes. It should also be noted that DNA
level copy changes may or may not correlate with the
expression data. Another issue even becomes more impor-
tant for microRNA expression studies when the precursor
microRNA levels and mature microRNA levels may not
linearly correlate with each other as Lin 28, an RNA-
binding protein, acts as a negative regulator and blocks
let-7 microRNA processing into the mature form in embry-
onic cells [45,46].
Such a DNA fold number profile of microRNAs on
genomic gain/loss regions may also be useful for delineat-
ing boundaries of certain instability regions, as well as for
identifying microRNA genes as potential oncogene and
tumor suppressor targets of the genomic instability regions,
along with protein coding genes. Given the number of
target mRNAs that a microRNA can bind, deregulated
expression of microRNAs can alter multiple pathways that
are important during the initiation or maintenance of the
neoplastic growth of cells.
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